Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: VIOXX

« Back to Dashboard
Vioxx is a drug marketed by Merck and is included in two NDAs. There are two patents protecting this drug.

The generic ingredient in VIOXX is rofecoxib. There is one drug master file entry for this compound. Additional details are available on the rofecoxib profile page.

Summary for Tradename: VIOXX


Clinical Trials for: VIOXX

Study of Vioxx and Radiation Therapy for Brainstem Glioma
Status: Terminated Condition: Glioma; Brain Neoplasms

CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen
Status: Completed Condition: Antiphospholipid Antibody Syndrome

A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee
Status: Completed Condition: Osteoarthritis of the Knee

Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
Status: Completed Condition: Prostate Cancer

Safety of Lumiracoxib in Patients With Osteoarthritis
Status: Completed Condition: Osteoarthritis

GECO: Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced Non-Small Cell Lung Cancer
Status: Completed Condition: Advanced Non-Small Cell Lung Cancer

A Double-Blind, Double-Dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain
Status: Terminated Condition: Acute Pain

A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)
Status: Completed Condition: Colorectal Adenoma

Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer
Status: Completed Condition: Colorectal Cancer

Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction
Status: Completed Condition: Pain

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
SUSPENSION;ORAL021052-001May 20, 1999DISCNNo6,063,811*PED<disabled>Y<disabled>
TABLET;ORAL021042-002May 20, 1999DISCNNo6,063,811*PED<disabled>Y<disabled>
SUSPENSION;ORAL021052-002May 20, 1999DISCNNo5,691,374*PED<disabled>Y<disabled>
TABLET;ORAL021042-002May 20, 1999DISCNNo5,691,374*PED<disabled>Y<disabled>
SUSPENSION;ORAL021052-001May 20, 1999DISCNNo5,691,374*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn